METHOD FOR COMPLEX TREATMENT OF METABOLIC SYNDROME Russian patent published in 2017 - IPC A61M21/00 A61B5/16 A61K31/155 A61K31/36 A61K31/4045 A61K31/593 A61P3/04 G01N33/48 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to therapy, endocrinology and cardiology, and can be used for complex treatment of metabolic syndrome. For this purpose diet therapy of reduced calorie 1200 kcal for women and 1500 kcal for men with limitation of carbohydrate-containing products and fats is carried out. Carbohydrate-containing products with glycemic index less than 40 are used. Metformin is also introduced. When initial body weight decreases by 5% and weight is stable for 2 months, diet caloric value is increased to calculated value, determined for patient by formula for calculation of day calorie recommended by WHO. Carbohydrate-containing products with glycemic index 40-69 are used until weight decreases to specified level. Introduction of metformin is continued for 6 months. In the process of treatment metformin is introduced in composition of "Reduxin Met-set", which includes capsules, containing sibutramine 10 mg and microcrystalline cellulose 158.5 mg, and metformin tablets 850 mg, which are introduced in dose 1 capsule in the morning and 1 tablet 2 times per day respectively. Additionally patient's state is assessed by subjective scale of asthenia assessment MFI-20 by subscale of psychic asthenia by questions 7, 11, 13, 19 and by subscale of motivation decrease by questions 4, 9, 15, 18. Answers are assessed by 5-point system items 4, 15, 7, 11 from "yes" - 1 point to "no" - 5 points, items 9, 18, 13, 19 from "yes" - 5 points to "no" - 1 point. Also performed is assessment of daytime sleepiness by sleepiness scale Epworth in points. Level 25 (OH) - of vitamin D is determined in blood serum. If sum of points is higher than 12 by subscale of psychic asthenia by questions 7, 11, 13, 19 or by scale of motivation decrease by questions 4, 9, 15, 18 and if sum of points is higher than 11 by sleepiness scale, as well as if content 25 (OH) - vitamin D is lower than 29 ng/ml, aquadetrim is additionally introduced during first 6 months in dose 2000 IU, then in dose 1000 IU during the following 6 months. Course of treatment also from the first day includes medication melaxen before going to bed 30 minutes before sleeping in dose 1.5 mg during the first week, then in dose 3 mg during the following 3 months, then in dose 3 mg during the first 15 days of each month for 3 months.

EFFECT: method ensures expressed dynamics of reducing abdominal obesity and other components of metabolic syndrome due to complex impact on insulin resistance, serotonergic system and increase of adaptation mechanisms of organism to stress situations, formation of rational food behaviour, reduction of vegetative and asthenic disorders.

8 tbl, 1 ex